U2AF1 S34Y/F

CI-VAR-00004054Explore in graph →CIViC 128

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Myeloid Leukemia2
U2AF1 S34Y/F	(diagnostic)	Diagnostic	B	Does Not Support Positive	3	submitted	EID218 Age, sex, FAB subtype and karyotypes were not statistically significant between AML patients with U2AF S34Y/F mutations and those who harbor wild type U2AF. PMID 23029227 · Qian et al., 2012 · Open in CIViC	civic
U2AF1 S34Y/F	(prognostic)	Prognostic	B	Does Not Support N/A	2	accepted	EID340 In patients with AML, complete remission rates are not different between patients who harbor the U2AF1 S34Y/F mutation and those with wild type U2AF1. PMID 23029227 · Qian et al., 2012 · Open in CIViC	civic
Myelodysplastic Syndrome1

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.